The A lzheimer's disease THE rapy with NE uroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trial

Christopher L H Chen; Purabi Reang Sharma; Boon Yeow Tan; Casuarine Low; Narayanaswamy Venketasubramanian

doi:10.1016/j.trci.2018.12.001

The A lzheimer's disease THE rapy with NE uroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trial

Alzheimers Dement (N Y). 2019 Jan 23:5:38-45. doi: 10.1016/j.trci.2018.12.001. eCollection 2019.

Authors

Christopher L H Chen¹, Purabi Reang Sharma², Boon Yeow Tan³, Casuarine Low⁴, Narayanaswamy Venketasubramanian⁵

Affiliations

¹ Department of Pharmacology, National University of Singapore, Clinical Research Centre, Singapore.
² Moleac Pte Ltd, Singapore.
³ St Luke's Hospital, Singapore.
⁴ Memory Ageing and Cognition Centre (MACC), National University Health System, Singapore.
⁵ Raffles Neuroscience Centre, 585 North Bridge Road, #02-00 Raffles Hospital, Singapore.

Abstract

Background: Dementia is a large and growing health care burden globally, and its major cause is Alzheimer's disease (AD). MLC901 (Neuroaid II) is a simplified form of MLC601 (Neuroaid), a Traditional Chinese Medicine with neuroprotective and neuroproliferative properties in cellular and animal models of brain injury. MLC601 has been shown to modulate amyloid precursor protein (APP) processing in human neuroblastoma cell cultures and increase the levels of soluble APPα. In addition, MLC901 has been shown to reduce tau phosphorylation in vitro. Hence, MLC901 may have possible multimodal actions and a disease-modifying effect in AD. In previous clinical studies, MLC601 has shown promising effects in AD.

Objective: To investigate the safety and efficacy of MLC901 add-on therapy to standard treatment in mild-to-moderate probable AD patients stable on standard treatment and to evaluate if MLC901 has a disease-modifying effect in AD.

Methods: This is a 6-month randomized, double-blind, placebo-controlled trial in mild-to-moderate probable AD where MLC901 will be given as an add-on therapy to standard AD treatment, followed by an extension study for another 6 months, where all subjects will be treated with open-label MLC901 in addition to standard treatment. The primary outcome is safety as measured by adverse events, vital signs, electrocardiogram, laboratory tests, and physical and neurological examinations. Secondary outcomes evaluating cognition, behavior, and activities of daily living at various time points include the Alzheimer's Disease Assessment Scale-cognitive subscale, Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change, Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Neuropsychiatric Inventory, and Mini-Mental State Examination.

Conclusion: MLC901 has the potential to improve cognition in AD patients. It may also have a role in delaying disease progression. This study will be the first to provide safety and efficacy data for MLC901 in mild-to-moderate probable AD patients already receiving standard therapy.

Keywords: Alzheimer's disease; Clinical trial; Disease progression; MLC901; Neuroaid II.